Background: The survival benefit of lymphadenectomy among patients with gallbladder cancer (GBC) remains poorly understood. Methods: Patients who underwent resection for GBC between 2000 and 2015 were identified from a US multi-institutional database. The therapeutic index (LNM rate multiplied by 3-year overall survival [OS]) was determined to assess the survival benefit of lymphadenectomy. Results: Among 449 patients, less than half had LNM (N = 183, 40.8%). The median number of evaluated and metastatic lymph nodes (LNs) was 3 (interquartile range [IQR]: 1-6) and 1 (IQR: 0-1), respectively. 3-year OS among patients with LNM in the entire cohort was 26.8%. The therapeutic index was lower among patients with T4 (5.9) or T1 (6.0) tumors as well as carbohydrate antigen (CA19-9) ≥200 UI/mL (6.0). Of note, a ---Washington University, St Louis, MO). Only patients who underwent curative-intent resection for a histologically confirmed GBC were included in this study. Patients who did not have LN examined, individuals who had an R2 surgical margin, as well as patients who died within 30-days after surgery were excluded. The Institutional Review Board of each participating institution approved this study. Patient demographic and clinicopathologic data were extracted including age, sex, race, body mass index (BMI), American Society of Anesthesiologist (ASA) class, the presence of preoperative biliary drainage, presentation (i.e. incidental vs non-incidental), preoperative serum level of carbohydrate antigen (CA) 19-9, type of liver resection, CBD resection, tumor size, American Joint Committee on Cancer (AJCC) T Stage, presence of LNM, number of LNs evaluated and LNM, tumor grade, lymphovascular or perineural invasion, as well as receipt of neoadjuvant and adjuvant therapy.
| Definition of therapeutic indexThe therapeutic index of LND was calculated by multiplying the incidence of LNM by the 3-year overall survival (OS) rate of individuals with LNM among different patient cohorts, as previously reported. 7,11 Specifically, the therapeutic index was utilized to estimate the survival benefit of LND relative to different clinicopathological and LN-related